Our Firm is representing numerous Risperdal gynecomastia plaintiffs in this litigation, and this case could provide valuable insight into how juries will rule in other cases involving allegations of male breast growth.
New York, New York (PRWEB) February 04, 2015
The bellwether trial of a Risperdal lawsuit (http://www.risperdallawsuit2014.com/) alleging that use of the atypical antipsychotic can cause gynecomastia in boys is moving forward in Pennsylvania’s Philadelphia Court of Common Pleas, Bernstein Liebhard LLP reports. According to court documents, a defense request for a mistrial was summarily denied by the Court on February 3rd, after the judge overseeing the trial decided that plaintiffs could introduce a new expert witness in the midst of the proceeding. (Case No. 1204-01997)
“Our Firm is representing numerous Risperdal gynecomastia plaintiffs in this litigation, and this case could provide valuable insight into how juries will rule in other cases involving allegations of male breast growth. We are pleased that the trial is moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal consultations to men and boys who allegedly developed gynecomastia due to their use of Risperdal.
Court documents indicate that more than 1,200 Risperdal lawsuits have been filed in the Pennsylvania litigation on behalf of plaintiffs who allegedly developed gynecomastia and other serious side effect due to its use. The case currently at trial involves a 20-year-old autistic man who allegedly experienced excessive breast growth due to his use of Risperdal as an 8-year-old child. Like other Risperdal gynecomastia claims pending in the proceeding, this lawsuit alleges that Johnson & Johnson and Janssen Pharmaceuticals concealed information about the drug’s potential to cause gynecomastia in boys. The companies are also accused of improperly marketing Risperdal for off-label use in children prior to the FDA’s 2006 decision to approve the drug for a number of pediatric indications. (In Re: Risperdal Litigation, Case Number 100300296)
For a number of years, Johnson & Johnson and Janssen have faced scrutiny over their handling of Risperdal. In November 2013, for example, the companies agreed to pay $2.2 billion to resolve criminal and civil charges regarding the marketing of several medications, including Risperdal. Among other things, the U.S. Department of Justice had accused the drug makers of improperly promoting Risperdal for off-label pediatric uses long before they were approved by the FDA. (U.S. District Court, Eastern District of Pennsylvania, 04-cv-1529)
Men and boys who allegedly developed gynecomastia due to Risperdal may be entitled to pursue their own claim against Johnson & Johnson and Janssen. To learn more about filing a Risperdal lawsuit, please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com